Metastasis of cancer cells is believed to be influenced by many factors which progress through several stages as cancer cells move from a primary lesion to metastatic sites. One of those factors, cell motility, plays an important role in the progression, especially after the extravasation. Motility-related protein 1 (MRP-1/CD9), which belongs to the transmembrane 4 superfamily of membrane proteins, is considered to inhibit cell motility (Miyake et al, 1991) . It has been demonstrated that the cells which expressed MRP-1/CD9 by transfection showed suppressed cell motility in vitro (Ikeyama et al, 1993 ). An inverse correlation was found between MRP-1/CD9 expression and metastases in breast cancer , and reduced MRP-1/CD9 gene expressions resulted in poor prognoses in non-small cell lung cancer . KAI1/CD82 is also one of the transmembrane 4 superfamily of membrane proteins which has similar effects, mediating metastasis and correlating positively with good prognosis in patients with nonsmall cell lung cancer (Adachi et al, 1996) and inversely with metastasis in prostatic cancers (Dong et al, 1995; Dong, 1996) . There were no studies of MRP-1/CD9 and KAI1/CD82 in oesophageal cancer. In this paper, we investigated expressions of MRP-1/CD9 and KAI1/CD82 in oesophageal cancer.
Immunohistochemical staining and evaluation
Immunohistochemical staining was performed using the avidinÐ biotin method. Tissue sections were deparaffinized and rehydrated in water. Endogenous peroxidase was blocked with 0.3% hydrogen peroxide for 30 min. Sections were rehydrated and washed with phosphate-buffered saline (PBS). Slides were then placed in plastic Coplin jars containing 10% sodium citrate. Jars were heated in the microwave oven five times for 3 min each time. After heating, the jars were removed from the oven and allowed to cool for 20 min. After the slides were rinsed in PBS three times for 5 min, they were incubated with 1.5% normal horse serum in PBS for 30 min at room temperature to block non-specific antibody reaction. Sections were incubated overnight at 4°C with anti-MRP-1/CD9 monoclonal antibody M31-15 at a dilution of 1:20 in PBS containing 1% bovine serum albumin. After six rinses in PBS, sections were incubated for 40 min at room temperature with biotinylated anti-mouse immunoglobulin G, followed by six washes with PBS, and then reacted with an avidinÐbiotin system, using 0.03% 3,3′-diaminobenzide tetrahydrochloride for about 4 min as chromogen. Sections were counterstained with MayerÕs haematoxylin. Negative controls were prepared by substituting normal mouse IgG for the primary antibody, and resulted in no detectable staining. In the case of KAI1/CD82 the immunostaining was conducted using the same methodology as stated above, with the exception that there was no antigen retrieval method by microwave oven. The antibody M31Ð15 was substituted with C33, a monoclonal antibody for KAI1/CD82 (Ueda et al, 1996) at a dilution of 1:100 in PBS containing 1% bovine serum albumin.
When more than 50% of the carcinoma cells in a given specimen were positively stained, the sample was classified as MRP-1/CD9-positive (+); when 5Ð50% were stained, as MRP-1/ CD9-reduced (±); and when less than 5% were stained, as negative (Ð) . When more than 10% of the carcinoma cells in a given specimen were positively stained, the sample was classified as KAI1/CD82-positive (+); and when less than 10% were stained, as KAI1/CD82-negative (Ð).
Statistical analysis
Statistical analysis was performed with χ 2 analysis and FisherÕs exact test. Survival curves of the patients were calculated by KaplanÐMeier method and analysis was done by log-rank test.
RESULTS
The expression of both MRP-1/CD9 and KAI1/CD82 appeared as positive on the cell membranes of the normal oesophageal epithelial cells ( Figure 1A , MRP-1/CD9; Figure 1B , KAI1/CD82), and reduced on the membrane of the cancer cells (Figure 2A , MRP-1/CD9; Figure 2B , KAI1/CD82). The number of reduced MRP-1/CD9 expressions significantly increased as tumours grew deeper (P = 0.0009). We found a significant inverse correlation between MRP-1/CD9 expression and lymph node metastasis (P = 0.0003), but not between MRP-1/CD9 expression and distant metastasis. Reduced expression of MRP-1/CD9 increased as the stage advanced (Table 1 ). In the 98 patients investigated, we found significant inverse correlation between MRP-1/CD9 expression and lymphatic invasion (P = 0.0204). In these same 98 patients the inverse correlation between MRP-1/CD9 expression and lymph node metastases was also confirmed (P = 0.0035) ( Table 2) . Correspondingly, the lymph node metastases correlated to lymphatic invasion (P = 0.004) ( Table 3 ).
The survival rates of 108 patients who received curative resection (R0) were examined. (Seventeen stage IV patients did not have organ metastasis except for cervical lymph nodal metastases, which were resected.) The 5-year survival rates of MRP-1/CD9-negative and MRP-1/CD9-reduced patients were significantly worse than those of MRP-1/CD9-positive patients (Figure 3) .
The expression of KAI1/CD82 was also inversely correlated to lymph node metastasis, but not to distant metastasis (Table 4) . Few cases stained KAI1/CD82-positive (9.6%; 10/104) in oesophageal cancer, therefore, we examined oesophageal dysplasias to investigate whether KAI1/CD82 expression was preserved in them. We Survival years *l k Figure 3 The relation between the influence of MRP-1/CD9 and survival rates. Survival curves of the patients were calculated by Kaplan-Meier method. The 5-year survival rates of MRP-1/CD9-negative and MRP-1/CD9-reduced patients showed significantly worse prognoses than that of positive patients (n = 108, curative cases). a log-rank test examined 24 dysplastic lesions which were taken from biopsied preoperative samples. Out of 24 dysplasias examined using the same immunohistochemical method, 20 (83.3%) cases of the dysplasia were defined as KAI1/CD82-positive. We then conducted immunohistochemical staining of MRP-1/CD9 on the same dysplasias, and 22 (91.7%) were defined as MRP-1/CD9-positive.
DISCUSSION
We have shown that reduced expression of both transmenbrane proteins, MRP-1/CD9 and KAI1/CD82, appear to be correlated to lymph node metastasis in oesophageal cancer patients. As there are very few reports concerning MRP-1/CD9 or KAI1/CD82 expressions in intestinal tumours or oesophageal cancer, we compared our study with those on other cancers. MRP-1/CD9 was reported to reduce its expression in proportion to the state of lymph node metastasis in non-small cell lung cancer , breast cancer and colon cancer (Cajot et al, 1997) . Reduced KAI1/CD82 expression was reported to be correlated with lymph node metastasis and poor prognoses in non-small cell lung cancer, especially in adenocarcinoma but not in squamous cell carcinoma (Adachi et al 1996) . We found compatible results indicating reduced expression of both MRP-1/CD9 and KAI1/CD82 correlated to lymph node metastasis in oesophageal squamous cell carcinoma. We could not, however, find an inverse correlation in distant metastatic cases. In these cases, almost all patientsÕ distant metastases were cervical lymph node metastases. Finding that MRP-1/CD9 expression was inversely correlated to lymphatic invasion may suggest that this molecular loss might affect mainly the closest sites to the primary lesions and thus lead to the local lymph node metastases. Distant lymph node metastasis may require other changes.
Reduced expression also correlated to poor prognoses in the MRP-1/CD9 expression in oesophageal carcinoma, as they had in other carcinomas. As most of the oesophageal carcinoma showed reduced expressions of KAI1/CD82, the correlation between KAI1/CD82 expressions and prognoses is not presented here.
Although the mechanism of the inhibitory effect on metastasis of these two transmembrane proteins has not been examined extensively, the inhibitory effect on metastasis by MRP-1/CD9 is believed to be due to suppression of cell motility. MRP-1/CD9 was also reported to interact with heparin-binding epidermal growth factor (EGF)-like growth factor associated with α3β1 integrin Nakamura et al, 1995) . These adhesional effects may play an essential role in the initiation of a metastatic cascade. The antibody to MRP-1/CD9 was reported to aggregate platelets and activate their function (Hato et al, 1988; Higashihara et al, 1990) . Platelets may release several growth factors which may facilitate tumour activation or growth.
We found a larger decrease in expression of KAI1/CD82 compared to MRP-1/CD9 in oesophageal cancer. Perhaps because of the specific nature of each antibody, the expression of KAI1/CD82 is thought to disappear at an earlier stage in carcinogenesis than MRP-1/CD9. Expression of both KAI1/CD82 and MRP-1/CD9 was preserved in many cases of dysplasia. The characteristic difference between the KAI1/CD82 and MRP-1/CD9 molecules may appear after dysplastic degradation in the oesophageal tumorigenesis.
KAI1/CD82 has a larger molecular weight, 29.610 kDa, than MRP-1/CD9, 24.28 kDa. Structurally, KAI1/CD82 has three Nglycosylation sites, while MRP-1/CD9 has one site (Boucheix C et al, 1991; Dong et al, 1995) . It is thought that N-glycosylation sites play an important role in the suppression of metastasis (Hakomori et al, 1989 ), but it is not well known what role these differences play. Though there were some differences between them, their basic characteristics seemed to resemble each other. Their expression disappeared in oesophageal cancer and loss of that expression seemed to correlate with the ability to initiate metastasis. Preserving those molecules might prevent the patient from metastases and knowledge of the level of expression may become a useful predictor of prognoses for oesophageal cancer patients.
